Factors influencing global antiretroviral procurement prices
Open Access
- 18 November 2009
- journal article
- Published by Springer Nature in BMC Public Health
- Vol. 9 (S1) , S6
Abstract
Antiretroviral medicines (ARVs) are one of the most costly parts of HIV/AIDS treatment. Many countries are struggling to provide universal access to ARVs for all people living with HIV and AIDS. Although substantial price reductions of ARVs have occurred, especially between 2002 and 2008, achieving sustainable access for the next several decades remains a major challenge for most low- and middle-income countries. The objectives of the present study were twofold: first, to analyze global ARV prices between 2005 and 2008 and associated factors, particularly procurement methods and key donor policies on ARV procurement efficiency; second, to discuss the options of procurement processes and policies that should be considered when implementing or reforming access to ARV programs.Keywords
This publication has 10 references indexed in Scilit:
- Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databasesBulletin of the World Health Organization, 2009
- Essential medicines pricing—reform neededThe Lancet, 2009
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- HIV/AIDS Drugs for Sub-Saharan Africa: How Do Brand and Generic Supply Compare?PLOS ONE, 2007
- What Strategies to Boost Production of Affordable Fixed-Dose Anti-Retroviral Drug Combinations for Children in the Developing World?Current HIV Research, 2007
- Negotiating antiretroviral drug prices: the experience of the Andean countriesHealth Policy and Planning, 2007
- Examining the production costs of antiretroviral drugsAIDS, 2006
- The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund2006
- Price Differentiation and Transparency in the Global Pharmaceutical MarketplacePharmacoEconomics, 2005
- Differential Pricing for Pharmaceuticals: Reconciling Access, R&D and PatentsInternational Journal of Health Care Finance and Economics, 2003